Kontafarma China, officially known as Kontafarma Limited, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Hong Kong. Founded in 2005, the company has established a strong presence across Asia, focusing on the development and distribution of innovative healthcare solutions. Specialising in prescription medications, over-the-counter products, and health supplements, Kontafarma is recognised for its commitment to quality and efficacy. The company’s unique approach combines advanced research with a deep understanding of local market needs, allowing it to deliver tailored solutions that enhance patient care. With a reputation for excellence, Kontafarma has achieved significant milestones, including strategic partnerships and a growing portfolio of proprietary products. As a trusted name in the industry, Kontafarma continues to strengthen its market position, contributing to the advancement of healthcare in the region.
How does Kontafarma China's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kontafarma China's score of 15 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kontafarma China, headquartered in Hong Kong, has made significant strides in managing its carbon emissions over recent years. In 2023, the company reported total emissions of approximately 1,783,000 kg CO2e, with Scope 1 emissions at about 1,057,000 kg CO2e and Scope 2 emissions at around 727,000 kg CO2e. This marks a notable reduction from previous years, particularly from 2021, when total emissions were approximately 11,000,000 kg CO2e, with Scope 1 at about 4,034,000 kg CO2e and Scope 2 at about 5,739,000 kg CO2e. In 2022, Kontafarma's total emissions were about 2,804,000 kg CO2e, indicating a downward trend in their carbon footprint. The company has consistently reported emissions across all three scopes, with Scope 3 emissions also being a focus, although specific figures for 2023 are not disclosed. Despite the positive trajectory in emissions reduction, Kontafarma has not publicly committed to specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other formal climate pledges. The absence of documented reduction targets suggests that while the company is actively reducing its emissions, it may not yet have formalised its long-term climate commitments. Overall, Kontafarma China's emissions data reflects a proactive approach to climate responsibility, with a clear trend towards lower emissions in recent years, particularly in Scope 1 and Scope 2 categories.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2017 | 2018 | 2019 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 1,543,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 189,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kontafarma China is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.